Industry News
Biotechnology Industry News
Amgen dons BigHat to bring AI insights to next-gen antibodies
Amgen dons BigHat to bring AI insights to next-gen antibodies ntaylor Mon, 01/10/2022 - 11:04
JPM 2022: Moderna finds Carisma’s macrophage tech compelling enough for $45M cancer research deal
JPM 2022: Moderna finds Carisma's macrophage tech compelling enough for $45M cancer research deal aarmstrong Mon, 01/10/2022 - 09:33
JPM 2022: Bristol Myers buoys cell therapy interests with $3B biobucks deal with Bayer-backed Century, $70M upfront to ArsenalBio
JPM 2022: Bristol Myers buoys cell therapy interests with $3B biobucks deal with Bayer-backed Century, $70M upfront to ArsenalBio klahucik Mon, 01/10/2022 - 08:19
BioMarin’s hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts
BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts ntaylor Mon, 01/10/2022 - 06:59
Maze Therapeutics navigates $190M financing round as it plots course to the clinic
Maze Therapeutics navigates $190M financing round as it plots course to the clinic fkansteiner Mon, 01/10/2022 - 05:55
Novartis splashes cash on COVID-19 antiviral, plans FDA filing as Molecular Partners links drug to drop in hospitalization, death
Novartis splashes cash on COVID-19 antiviral, plans FDA filing as Molecular Partners links drug to drop in hospitalization, death ntaylor Mon, 01/10/2022 - 04:50
JPM, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more
JPM, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more badams Mon, 01/10/2022 - 04:25
JPM22, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more
JPM22, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and more badams Mon, 01/10/2022 - 04:25
JPM 2022: Bayer taps CRISPR science from Doudna’s lab in $1B biobucks Mammoth gene therapy deal
JPM 2022: Bayer taps CRISPR science from Doudna's lab in $1B biobucks Mammoth gene therapy deal aliu Sat, 01/08/2022 - 06:42
JPM 2022: Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucks
JPM 2022: Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucks aarmstrong Fri, 01/07/2022 - 12:50
Merck leans into AI with $610M in biobucks for Absci drug discovery pact
Merck leans into AI with $610M in biobucks for Absci drug discovery pact aarmstrong Fri, 01/07/2022 - 10:38
Atea sticks it out with failed COVID-19 antiviral but also raids Merck’s store room for hepatitis C drug
Atea sticks it out with failed COVID-19 antiviral but also raids Merck's store room for hepatitis C drug aarmstrong Fri, 01/07/2022 - 10:02
Cytokinetics finds worldwide partner in Royalty Pharma for heart failure drug, snags up to $450M to extend runway
Cytokinetics finds worldwide partner in Royalty Pharma for heart failure drug, snags up to $450M to extend runway aarmstrong Fri, 01/07/2022 - 09:11
AstraZeneca picks up new weapon in rare disease fight with Alnylam and Pfizer, paying $30M for rights to an early-phase asset
AstraZeneca picks up new weapon in rare disease fight with Alnylam and Pfizer, paying $30M for rights to an early-phase asset ntaylor Fri, 01/07/2022 - 07:35
Chutes & Ladders—Maraganore’s post-Alnylam ambitions take flight
Chutes & Ladders—Maraganore's post-Alnylam ambitions take flight fkansteiner Thu, 01/06/2022 - 14:53
Aligos says stop right now to lead hep B med after fruitless phase 1 data
Aligos says stop right now to lead hep B med after fruitless phase 1 data aarmstrong Thu, 01/06/2022 - 14:49
Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia
Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia ntaylor Thu, 01/06/2022 - 11:51
Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs
Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs aarmstrong Thu, 01/06/2022 - 09:19
Sanofi tears up Sangamo cell therapy deal in pivot to off-the-shelf approaches
Sanofi tears up Sangamo cell therapy deal in pivot to off-the-shelf approaches ntaylor Thu, 01/06/2022 - 08:08
Novartis taps Alnylam for ambitious push to fix liver function
Novartis taps Alnylam for ambitious push to fix liver function ntaylor Thu, 01/06/2022 - 07:29